To review the currently available information on the once-daily combination of niacin extended-release (ER)/lovastatin in the treatment of patients with hypercholesterolemia and mixed dyslipidemia at high risk for cardiovascular events.
DATA SOURCES
MEDLINE (1966–July 2002) was searched for primary and review articles. Data from the manufacturer were also included.
STUDY SELECTION/DATA EXTRACTION
All articles and product labeling deemed relevant to the combination of niacin and statins (i.e., lovastatin) were included for review. English-language studies selected for inclusion were limited to those with human subjects.
DATA SYNTHESIS
The Food and Drug Administration approved a new fixed-dose combination of niacin-ER/lovastatin, which is administered once daily. The efficacy and safety of the combined agent have been proven to be similar to either component used alone or in combination for management of hyperlipidemia and mixed dyslipidemia.
CONCLUSIONS
Elevated low-density lipoprotein cholesterol (LDL-C) is independently associated with a higher risk for cardiovascular events. Lowering of elevated LDL-C concentrations with statin monotherapy may be insufficient in patients at high risk for cardiovascular events. In fact, consideration of elevated triglycerides (TGs) and/or low concentrations of high-density lipoprotein cholesterol (HDL-C) in patients with elevated LDL-C places them at greater risk. The addition of niacin may enhance or improve the lipid profile of those who require a further decrease of TGs and/or increase of HDL-C even after stable statin therapy. Niacin-ER offers efficacy similar to that of immediate-release niacin, but minimal myopathy and hepatotoxicity (compared with sustained-release niacin). Although no clinical outcomes are available, current evidence shows that the combination product offers adequate lowering of LDL-C and TGs and increasing HDL-C. The data suggest that therapy with the niacin-ER and lovastatin combination product is safe and does not increase the incidence of adverse effects.
THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT ACPE UNIVERSAL PROGRAM NUMBER: 407-000-03-003-H01
. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994; 344: 1383–9.
2.
. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N Engl J Med1998; 339: 1349–57.
3.
. DownsJR, ClearfieldM, WeisS, WhitneyE, ShapiroDR, BeerePA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/Tex-CAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA1998; 279: 1615–22.
4.
. ShepherdJ, CobbeSM, FordI, IslesCG, LorimerAR, MacFarlanePW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med1995; 333: 1301–7.
5.
. SacksFM, PfefferMA, MoyeLA, RouleauJL, RutherfordJD, ColeTG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med1996; 335: 1001–9.
6.
. AmarencoP.Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction. Neurology2001; 57 (suppl 2): S35–44.
7.
. HarperCR, JacobsonTA. New perspectives on the management of low levels of high-density lipoprotein cholesterol. Arch Intern Med1999; 159: 1049–57.
8.
. MRC/BHFHeart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Heart Protection Study Collaborative Group. Lancet2002; 360: 7–22.
. SerruysPW, de FeyterP, MacayaC, KokottN, PuelJ, VrolixM, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA2002; 287: 3215–22.
11.
. GordonDJ, RifkindBM. High-density lipoproteins — the clinical implications of recent studies. N Engl J Med1989; 321: 1311–6.
12.
. AssmannG, SchulteH.Modelling the Helsinki Heart Study by means of risk equations obtained from the PROCAM Study and the Framingham Heart Study. Drugs1990; 40 (suppl 1): 13–8.
13.
. AustinMA, HokansonJE, EdwardsKL. Hypercholesterolemia as a cardiovascular risk factor. Am J Cardiol1998; 81 (4A): 7B–12B.
14.
. JeppesenJ, HeinHO, SuadicaniP, GyntelbergF.Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation1998; 97: 1029–36.
15.
. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP)Expert Panel on Detection, Evaluation And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA2001; 285: 2486–97.
16.
. TonkinA.High-density lipoprotein cholesterol and treatment guidelines. Am J Cardiol2001; 88 (12A): 41N–4N.
17.
. RubinsHB, RobinsSJ, CollinsD, FyeCL, AndersonJW, ElamMB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med1999; 341: 410–8.
18.
. GuytonJR, BlazingMA, HagarJ, KashyapML, KnoppRH, McKenneyJM, et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Arch Intern Med2000; 160: 1177–84.
19.
. McKenneyJM, ProctorJD, HarrisS, ChinchiliVM. A comparison of the efficacy and toxic effects of sustained- vs. immediate-release niacin in hypercholesterolemic patients. JAMA1994; 271: 672–7.
20.
. LuriaMH. Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol ratio. Arch Intern Med1988; 148: 2493–5.
21.
. Clofibrate and niacin in coronary heart disease. The Coronary Drug Project Research Group. JAMA1975; 231: 360–81.
22.
. CannerPL, BergeKG, WengerNK, StamblerJ, FriedmanL, PrineasRJ, et al. Fifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol1986; 8: 1245–55.
23.
. Product information. Advicor (niacin extended-release and lovastatin tablets). Miami, FL: Kos Pharmaceuticals, November 2001.
24.
. BrownMD, GoldsteinJL. A receptor-mediated pathway for cholesterol homeostasis. Science1986; 232: 34–47.
25.
. Von EckardsteinA, NoferJ, AssmannG.High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol2001; 21: 13–27.
26.
. SchaeferJR, SchweerH, IkewakiK, StrackeH, SeyberthHJ, KaffarnikH, et al. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis1999; 144: 177–84.
27.
. KnoppRH, AlagonaP, DavidsonM, GoldbergAC, KafonekSD, KashyapM, et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night vs. plain niacin in the management of hyperlipidemia. Metabolism1998; 47: 1097–104.
28.
. KashyapML. Mechanistic studies of high-density lipoproteins. Am J Cardiol1998; 82: 42U–8U.
29.
. SuperkoHR, KraussRM. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis1992; 95: 69–76.
30.
. GuptaEK, ItoMK. Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia. Heart Dis2002; 4: 124–37.
31.
. PiephoRW. The pharmacokinetics and pharmacodynamics of agent proven to raise high-density lipoprotein cholesterol. Am J Cardiol2000; 86 (12A): 35L–40L.
32.
. CapuzziDM, GuytonJR, MorganJM, GoldbergAC, KreisbergRA, BruscoOA, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol1998; 82 (12A): 74U–81U.
33.
. GoldbergA, AlagonaP, CapuzziDM, GuytonJ, MorganJM, RodgersJ, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol2000; 85: 1100–5.
34.
. GoldbergAC. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. Am J Cardiol1998; 82 (12A): 35U–8U.
35.
. IllingworthDR, BaconS.Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs. Arteriosclerosis1989; 9 (suppl 1): I-121–34.
36.
. ReavenP, WitztumJL. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med1988; 109: 597–8.
37.
. NormanDJ, IllingworthDR, MunsonJ, HosenpudJ.Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin (letter). N Engl J Med1988; 318: 46–7.
38.
. DavignonJ, RoedererG, MontignyM, HaydenMR, TanMH, ConnellyPW, et al. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol1994; 73: 339–45.
39.
. JacobsonTA, ChinMM, FromellGJ, JokubaitisLA, AmorosaLF. Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol1994; 74: 149–54.
40.
. TsalamandrisC, PanagiotopoulosS, SinhaA, CooperME, JerumsG.Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidemia in diabetic and non-diabetic patients. J Cardiovasc Risk1994; 1: 231–9.
41.
. VacekJL, DittmeierG, ChiarelliT, WhiteJ, BellHH. Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia. Am J Cardiol1995; 76: 182–4.
42.
. O'KeefeJHJr, HarrisWS, NelsonJ, WindsorSL. Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am J Cardiol1995; 76: 480–4.
43.
. GardnerSF, SchneiderEF, GranberryMC, CarterIR. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin. Pharmacotherapy1996; 16: 419–23.
44.
. PasternakRC, BrownLE, StonePH, SilvermanDI, GibsonCM, SacksFM. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and “normal” cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group. Ann Intern Med1996; 125: 529–40.
45.
. GardnerSF, MarxMA, WhiteLM, GranberryMC, SkeltonDR, FonsecaVA. Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control. Ann Pharmacother1997; 31: 677–82.
46.
. BrownBG, BardsleyJ, PoulinD, HillgerLA, DowdyA, MaherVM, et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dL in patients with hyperlipidemia and coronary artery disease. Am J Cardiol1997; 80: 111–5.
47.
. BrownBG, ZhaoXQ, ChaitA, FisherLD, CheungMC, MorseJS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med2001; 345: 1583–92.
48.
. MorganJM, CapuzziDM, GuytonJR, CentorRM, GoldbergR, RobbinsDC, et al. Treatment Effect of Niaspan, a Controlled-release Niacin, in Patients With Hypercholesterolemia: A Placebo-controlled Trial. J Cardiovasc Pharmacol Ther1996; 1: 195–202.
49.
. MorganJM, CapuzziDM, GuytonJR. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol1998; 82 (12A): 29U–34U.
50.
. GuytonJR, GoldbergAC, KreisbergRA, SprecherDL, SuperkoHR, O'ConnorCM. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol1998; 82: 737–43.
51.
. KashyapML, McGovernME, BerraK, GuytonJR, KwiterovichPO, HarperWL, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol2002; 89: 672–8.
52.
. FurbergCD, PittB.Withdrawal of cerivastatin from the world market (commentary). Curr Control Trials Cardiovasc Med2001; 2: 205–7.
. GrundySM, VegaGL, McGovernME, TullochBR, KendallDM, Fitz-PatrickD, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Arch Intern Med2002; 162: 1568–76.
55.
. WolfeML, VartanianSF, RossJL, BansavichLL, MohlerER3rd, MeagherE, et al. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol2001; 87: 476–9A7.
56.
. Drug topics red book update. Montvale, NJ: Medical Economics, April 2002.
